Fulcrum Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Fulcrum Therapeutics has a total shareholder equity of $235.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $257.7M and $22.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$236.22m |
| Equity | US$235.19m |
| Total liabilities | US$22.50m |
| Total assets | US$257.69m |
Recent financial health updates
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Feb 11
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Oct 28We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Jul 11We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
Oct 18Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth
Apr 09Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Dec 09Recent updates
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Feb 11We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Oct 28We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Jul 11What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today
Nov 17We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
Oct 18Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts
Aug 13Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M
Aug 11Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave
Jul 11Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder
Jul 05Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling
Jun 27These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat
May 10Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth
Apr 09Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Dec 09Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point
Sep 03Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results
Aug 12News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts
Aug 11Industry Analysts Just Upgraded Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Revenue Forecasts By 83%
May 12We're Hopeful That Fulcrum Therapeutics (NASDAQ:FULC) Will Use Its Cash Wisely
May 07Fulcrum Therapeutics beats on revenue
May 06Financial Position Analysis
Short Term Liabilities: FULC's short term assets ($242.2M) exceed its short term liabilities ($13.7M).
Long Term Liabilities: FULC's short term assets ($242.2M) exceed its long term liabilities ($8.8M).
Debt to Equity History and Analysis
Debt Level: FULC is debt free.
Reducing Debt: FULC has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FULC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: FULC has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 22.8% each year.